The U.S. Food and Drug Administration has approved Cinqair (reslizumab) for the treatment of severe asthma in combination with other asthma medicines in patients 18 years of age or older. Read More »

The U.S. Food and Drug Administration (FDA) has approved Taltz (ixekizumab), which was designed for the treatment of adults with moderate-to-severe plaque psoriasis. Read More »

The U.S. Food and Drug Administration (FDA) announced this week the approval of Anthim (oblitoxaximab) injection for the treatment of inhalational anthrax to be used in combination with antibacterial drugs. Read More »

Amgen has announced that it will present 19 abstracts associated with its cardiovascular portfolio that will include new data from the evaluation of Repatha (evolocumab) at the American College of Cardiology’s 65th Annual Scientific Session (ACC 16). Read More »

Cellectis has entered into an agreement with Takara Bio Inc. for the supplying and licensing of RetroNectin, a recombinant human fibronectin fragment. Read More »

The U.S. Food and Drug Administration (FDA) has announced labeling changes that will be required class-wide for immediate-release (IR) opioid pain medicines. Read More »

Rockwell Medical has announced that the China Food and Drug Administration (CFDA) has accepted its Triferic drug product submission. Read More »

The ASHP’s Match program has continued to show progress and is continuing to grow at a rapid pace. Read More »

Advaxis has announced that data from its ADXS-HER2 dose-escalation study in canine osteosarcoma (OSA) has been published in Clinical Cancer Research, an online publication of the American Association for Cancer Research (AACR) on March 18. Read More »

Amgen and UCB have announced positive high quality results from the pivotal Phase 3 placebo-controlled study evaluatIng the efficiency and safety of romosozumab in treating men with osteoporosis (BRIDGE) trial. Read More »

The National Association of Chain Drug Stores (NACDS) held its eighth annual RxIMPACT Day on Capitol Hill this week to showcase grassroots activism and political engagement. Read More »

The U.S. Senate this week passed the National Association of Chain Drug Stores-backed Ensuring Patient Access and Effective Drug Enforcement Act of 2016 (S. 483). Read More »

Incyte Corp. has announced that it will be presenting 10 abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2016 that will feature data from its emerging development portfolio. Read More »

The American Pharmacists association (APhA) has announced that its House of Delegates voted to enact a new policy regarding the labeling and measurement of oral liquid medications at the APhA Annual Meeting in Baltimore, Maryland. Read More »

Astellas Pharm Inc. announced this week that it has named a Nadeshiko Brand component by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) for its excellence in the promotion and involvement of women in the workplace. Read More »

Sanofi and Regeneron Pharmaceuticals recently announced that both companies strongly oppose the U.S. District Court jury decision for two patents involving Amgen antibodies designed to target PCSK9 (proprotein canvertase subtilisin/kexin type 9) that have been deemed valid. Read More »

Orexigen Therapeutics and Takeda Pharmaceuticals U.S.A., a subsidiary of Takeda Pharmaceutical Co., announced earlier this week that they have agreed on terms to terminate the Amended and Restated Collaboration Agreement for CONTRAVE (naltrexone HCI/bupropion HCI). All rights to the medication will belong to Orexigen. Read More »

Walgreens and OptumRx have announced a partnership that will result in the creation of a new pharmacy solution program aimed at changing prescription drug needs to benefit the consumer and help employers, health plans and members receive higher health outcomes and save more. Read More »

The Takeda Pharmaceutical Co. and Frazier Healthcare Partners recently launched Outpost Medicine, a new company in the biopharmaceutical field that will focus on developing new treatment options for urologic and gynecologic diseases and disorders. Read More »

Pfizer has announced that it will be presenting new data based on the research of tofacitinib in ulcerative colitis (UC) and Crohn’s disease at the 11th Congress of ECCO, which is scheduled for March 16-19 in Amsterdam. Read More »